Skip to main content

Table 3 Baseline characteristics of in the 472 HCC patients

From: The association of liver function and quality of life of patients with liver cancer

Variable

N

%

Mean ± SD

Clinical data

 Age < = 65

328

69

60 ± 12

 Male gender

419

89

 

ECOG

 0

144

31

 

 1

299

63

 

 ≥ 2

29

6

 

Cirrhosis (radiological)

278

59

 

Tumor morphology

 Uninodular

122

26

 

 Multinodular

143

30

 

 Diffuse

207

44

 

Extrahepatic metastasis (nodal or distant)

108

23

 

Portal vein thrombosis

152

32

 

Hepatitis B surface antigen +

386

82

 

Hepatitis C antibody +

30

6

 

α-feto protein ≥200 mg/ml

250

53

 

ALBI score

472

 

−2.29 ± 1.33

 Grade 1

155

32.8

 

 Grade 2

265

56.2

 

 Grade 3

52

11.0

 

MELD score

472

 

9.08 ± 4.05

 Grade 1 (< 10)

319

67.6

 

 Grade 2 (10–14)

109

21.4

 

 Grade 3 (> 14)

52

11.0

 

Child-Pugh class

 A

319

67.6

 

 B

130

27.5

 

 C

23

4.9

 

Albumin

472

100

37.4 ± 15.2

Bilirubin

472

100

32.8 ± 45.7

INR

472

100

1.15 ± 0.17

ALP

472

100

193.4 ± 155.8

ALT

472

100

77.3 ± 69.4

Albumin-to-ALP ratio

472

100

0.29 ± 0.22

ALP-to-platelet ratio

472

100

1.20 ± 1.19

Presence of ascites

122

25.8

 

Hemoglobin < 10 g/dL

27

6

 

White cell count > 10 × 109/L

64

14

 

Platelet count < 100 × 109/L

33

7

 

1st line Treatment

 Surgical treatment

54

12

 

 Local ablative therapies

29

6

 

 Trans-arterial therapies

116

25

 

 Systemic therapies

91

19

 

 Best supportive care alone

182

38

 
  1. EORTC European Organization for Research and Treatment of Cancer, ECOG Eastern Cooperative Oncology Group, ALBI Albumin-bilirubin, MELD Model for End-stage Liver Disease, INR international normalized ratio, ALP alkaline phosphatases, ALT alanine transaminase